About Hormone Deficiency
Hormone deficiency, also known as dwarfism or pituitary dwarfism, is a condition caused by insufficient levels of growth hormone in the body. GHD children have abnormally short stature but normal body proportions. GHD can be present at birth or develop later in life (acquired). Human growth hormone (hGH) or somatotropin is a peptide hormone that is responsible in humans for cell reproduction, growth stimulation, and cell regeneration. Human growth hormone (GH) deficiency occurs when the pituitary gland is unable to synthesise enough hGH. This deficiency is treated by administering recombinant hGH subcutaneously. Human growth hormone deficiency can be caused by a variety of genetic disorders, including Turner syndrome and Prader-Willi syndrome, resulting in shorter-than-average height and delayed puberty.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
The market for Hormone Deficiency is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hormone Deficiency market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Merck Serono (Germany), Pfizer (United States), Novo Nordisk (Denmark), F. Hoffmann-La Roche (Switzerland), Anhui Anke Biotechnology (Group) (China), BioPartners (Switzerland), Eli Lilly (United States), Ferring Pharmaceuticals (Switzerland), GeneScience Pharmaceuticals (China), Ipsen (France) and Teva Pharmaceutical Industries (Israel) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global Hormone Deficiency market by , Application (Hospitals and Clinics) and Region.
On the basis of geography, the market of Hormone Deficiency has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medication, the sub-segment i.e. Genotropin will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Types of Hormonal Disorders, the sub-segment i.e. Adrenal will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Dry skin will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
On 25 May 2022, Aeterna Zentaris Inc., announced that Ghryvelin (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults , is available to healthcare professionals across Europe. This availability is possible thanks to Aeterna’s licensing partner, Consilient Health, Ltd., a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East.
On 26 August 2021, The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, according to an industry press release. Lonapegsomatropin-tcgd injection (Skytrofa, Ascendis) is approved for children who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.
Market Drivers
- Increasing Prevalence Of Growth Disorders
- Surge In Number Of Geriatric Population
Opportunities
- Surge In Healthcare Expenditure
- Rising Awareness Level Among Individual For Hormone Deficiency
Restraints
- High Cost Associated With The Treatment Will Obstruct The Growth Rate Of Market
- Increasing In Side Effects Of Hormone Deficiency
Challenges
- Lack Of Advanced Healthcare Infrastructure In Developing Countries
- Companies Have To Comply With FDA Regulation
Key Target Audience
New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.